On April 21, 2020, AIM ImmunoTech Inc. entered into a Mutual Confidentiality Agreement with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. (collectively, the "Entities") for the purpose of evaluation and discussion for certain business relationships concerning a COVID-19 therapeutic and vaccine. Current discussions with the Entities are preliminary and we anticipate that, if the parties determine to proceed, initial activity will consist of preclinical animal studies of Ampligen.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4 USD | -2.08% | -6.98% | -9.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.07% | 20.38M | |
-2.59% | 102B | |
+2.23% | 96.09B | |
+2.13% | 22.28B | |
-17.09% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.90% | 16.09B | |
+6.51% | 13.83B | |
+32.26% | 11.97B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM ImmunoTech Inc. Enters into Mutual Confidentiality Agreement with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd